A decade in charge of the EMA
This article was originally published in SRA
European Medicines Agency executive director Thomas Lönngren talks to Maureen Kenny about transparency, legacy and the lack of a successor in the run-up to his departure from the agency.
You may also be interested in...
The European Commission is deciding on the terms of reference of an external study, to be completed in 2018, in order to comply with its legal obligation of publishing a general report every 10 years on the experience acquired with various EU marketing authorization procedures for human drugs.
The EU product information for Ibrance, Verzenios and Kisqali is being updated to include interstitial lung disease and pneumonitis. The change has already been implemented in the US.